Language selection

Government of Canada

Search

Coronavirus disease (COVID-19): Canada’s response

On this page

How Canada is responding to COVID-19

For detailed information on Canada's whole-of-government actions to respond to the outbreak, refer to the Government of Canada's response to COVID-19.

Economic and financial support

To learn more about Canada’s actions to help Canadians and businesses facing hardship as a result of the COVID-19 outbreak, refer to Canada’s COVID-19 Economic Response Plan.

Travel measures

The Government of Canada is continually assessing travel risks for Canadians. An official global travel advisory is in effect: Avoid all non-essential travel outside of Canada until further notice. In addition, a pandemic COVID-19 travel health notice with travel health advice for Canadians has also been issued.

All international passenger flight arrivals have been redirected to 1 of 4 airports:

Additional information on travel and border measures is available.

Support for Canadians abroad

To help Canadians return home or cope with challenges they are facing while travelling, the Government of Canada has created the COVID-19 Emergency Loan Program for Canadians Abroad.

The Program will provide the option of an emergency loan to Canadians in need of immediate financial assistance to return home or to temporarily cover their life-sustaining needs while they work toward their return.

Global Affairs Canada is providing 24/7 consular support to Canadians abroad affected by COVID-19 through the Emergency Watch and Response Centre and through consular staff at its network of missions.

Collaboration

The Federal/Provincial/Territorial Public Health Response Plan for Biological Events has been activated to ensure a coordinated response across Canada.

A special advisory committee has been established to advise the Deputy Ministers of Health on the coordination, public health policy and technical content related to this outbreak. This committee consists of the members of the Pan-Canadian Public Health Network Council and the Council of Chief Medical Officers of Health.

The Public Health Agency of Canada is working closely with partners domestically and around the world, including the World Health Organization (WHO), to respond to this outbreak.

Canada's National Microbiology Laboratory (NML) has developed a real-time reverse transcription-polymerase chain reaction (rRT-PCR) test that can diagnose COVID-19 from clinical specimens. The NML is working collaboratively with Canadian provincial public health laboratories to ensure there is additional testing capacity in multiple jurisdictions.

At this time, the NML also supports the use of other international assays that have been posted publicly.

Further collaborative scientific studies to investigate the virus are underway.

The Government of Canada is working with international regulators to help fast-track clinical trials and applications for vaccines, treatments and diagnostic tests. The International Coalition of Medicines Regulatory Authorities held a global medicines regulators web meeting on March 18, 2020. Discussions included regulatory considerations for anticipated COVID-19 vaccine candidates to advance regulatory convergence. A key objective of the meeting was to discuss and agree on an approach to the requirements to support first-in-human clinical trials. The press release and meeting report are available for access. Health Canada has also engaged with international regulatory partners under the Australia-Canada-Singapore-Switzerland Consortium to explore potential collaboration on regulatory issues related to COVID-19.

We are also working closely with international regulatory partners, including the European Medicines Agency, the United States Food and Drug Administration, and the Therapeutic Goods Administration, to share information on any signals of global supply disruptions.

For clinical trial sponsors

Companies and researchers with drugs, medical devices, or natural health products that may be effective in treating or diagnosing COVID-19 are encouraged to contact us to facilitate clinical trials.

Clinical trials are studies to find out whether a drug or medical device is safe and effective for people. We can authorize a clinical trial quickly in urgent situations. We also publish a list of all clinical trials authorized in Canada.

Please contact us at:

Drug and medical device supply monitoring

The Government of Canada is actively monitoring the novel COVID-19 and its impact on the supply of prescription and over-the-counter drugs, natural health products and medical devices in Canada. We do this through regular contact with:

We are aware that there may be supply disruptions related to COVID-19 and are monitoring the situation closely.

Companies that market prescription drugs for human use in Canada must report anticipated or actual drug shortages on Drug Shortages Canada. We have contacted companies to remind them of this requirement. Industry stakeholder associations have also been asked to notify us of any early signals of shortages related to COVID-19. Drug and medical device shortage signals can also be reported by the provinces and territories, healthcare professionals or the public.

We will continue to use all available tools to help manage critical national shortages when they happen, and work with partners so that Canadians have access to the medications they need. Learn more about drug shortages in Canada.

Related links

What COVID-19 information do you need?

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: